CNS Pharmaceuticals Inc (CNSP) - Total Liabilities
Based on the latest financial reports, CNS Pharmaceuticals Inc (CNSP) has total liabilities worth $4.58 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CNS Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
CNS Pharmaceuticals Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how CNS Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
CNS Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of CNS Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Henderson European Focus Trust Plc
LSE:HET
|
UK | GBX31.23 Million |
|
Metals Creek Resources Corp
V:MEK
|
Canada | CA$292.49K |
|
Mex Polska S.A.
WAR:MEX
|
Poland | zł69.58 Million |
|
PRS Reit PLC
LSE:PRSR
|
UK | GBX442.94 Million |
|
Adelong Gold Ltd
AU:ADG
|
Australia | AU$702.45K |
|
China Ouhua Winery Holdings
KLSE:5188
|
Malaysia | RM6.99 Million |
|
Unith Ltd
AU:UNT
|
Australia | AU$2.50 Million |
|
DXN Ltd
AU:DXN
|
Australia | AU$10.91 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down CNS Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CNSP stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 64.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.98 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CNS Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CNS Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of CNS Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.10 Million | +62.46% |
| 2024-12-31 | $2.52 Million | -58.84% |
| 2023-12-31 | $6.13 Million | +24.65% |
| 2022-12-31 | $4.92 Million | +130.40% |
| 2021-12-31 | $2.14 Million | +12.08% |
| 2020-12-31 | $1.91 Million | +512.68% |
| 2019-12-31 | $311.00K | -74.77% |
| 2018-12-31 | $1.23 Million | +458.44% |
| 2017-12-31 | $220.73K | -- |
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate ca… Read more